VEA
KPTI icon

Virtus ETF Advisers’s Karyopharm Therapeutics KPTI Stock Holding History

Virtus ETF Advisers’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-2,958
Closed -$258K – 391
2021
Q3 		$258K Sell
2,958
-271
-8% -$28.1K 0.11% 216
2021
Q2 		$500K Buy
3,229
+550
+21% +$79.8K 0.21% 150
2021
Q1 		$423K Buy
2,679
+73
+3% +$15.4K 0.18% 171
2020
Q4 		$605K Buy
2,606
+273
+12% +$63.3K 0.25% 112
2020
Q3 		$511K Buy
2,333
+196
+9% +$47.9K 0.27% 131
2020
Q2 		$607K Sell
2,137
-205
-9% -$60.6K 0.29% 115
2020
Q1 		$675K Sell
2,342
-198
-8% -$54.6K 0.28% 138
2019
Q4 		$730K Sell
2,540
-410
-14% -$88.9K 0.12% 154
2019
Q3 		$426K Sell
2,950
-164
-5% -$22.2K 0.09% 186
2019
Q2 		$280K Buy
3,114
+1,288
+71% +$103K 0.06% 248
2019
Q1 		$160K Sell
1,826
-222
-11% -$24.6K 0.34% 94
2018
Q4 		$288K Buy
2,048
+299
+17% +$50.4K 0.05% 127
2018
Q3 		$447K Sell
1,749
-1,250
-42% -$346K 0.05% 142
2018
Q2 		$764K Sell
2,999
-2,423
-45% -$599K 0.68% 57
2018
Q1 		$1.09M Buy
5,422
+2,957
+120% +$590K 0.95% 28
2017
Q4 		$355K Buy
2,465
+80
+3% +$12.8K 0.45% 82
2017
Q3 		$393K Buy
2,385
+218
+10% +$31.2K 0.05% 113
2017
Q2 		$294K Buy
2,167
+143
+7% +$21.2K 0.04% 129
2017
Q1 		$390K Buy
2,024
+194
+11% +$31.1K 0.07% 115
2016
Q4 		$258K Sell
1,830
-211
-10% -$28.5K 0.08% 133
2016
Q3 		$298K Hold
2,041
– – 0.14% 100
2016
Q2 		$205K Buy
2,041
+846
+71% +$110K 0.15% 134
2016
Q1 		$160K Buy
+1,195
New +$132K 0.22% 113

Other funds holding KPTI

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return
LOAMS
Lombard Odier Asset Management (Switzerland) Petit-Lancy, Switzerland $2.63B AUM 31.52% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.66B AUM 11.67% 1-Year Est. Return

Virtus ETF Advisers's KPTI Position: Q4 2021 in Review

Virtus ETF Advisers sold out of Karyopharm Therapeutics (KPTI) in Q4 2021, closing a stake of 2,958 shares — an estimated $258K sold.

Virtus ETF Advisers first reported a position in KPTI in Q1 2016 and held it in 23 quarters. The position peaked at $1.09M in Q1 2018. 143 funds tracked by Wall St. Rank hold KPTI as of Q4 2021.

  • Virtus ETF Advisers reported no remaining Karyopharm Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Virtus ETF Advisers sold 2,958 Karyopharm Therapeutics shares in Q4 2021, an estimated $258K.
  • Virtus ETF Advisers first reported a position in Karyopharm Therapeutics in Q1 2016 and held it in 23 quarters.
  • Virtus ETF Advisers's Karyopharm Therapeutics position peaked at $1.09M in Q1 2018.
  • 143 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q4 2021.

Based on Virtus ETF Advisers's 13F filing for Q4 2021, filed 14 Feb 2022.